CN102940683B - Chinese medicinal compound composition for treating liver cancer and preparation method thereof - Google Patents
Chinese medicinal compound composition for treating liver cancer and preparation method thereof Download PDFInfo
- Publication number
- CN102940683B CN102940683B CN2012104512777A CN201210451277A CN102940683B CN 102940683 B CN102940683 B CN 102940683B CN 2012104512777 A CN2012104512777 A CN 2012104512777A CN 201210451277 A CN201210451277 A CN 201210451277A CN 102940683 B CN102940683 B CN 102940683B
- Authority
- CN
- China
- Prior art keywords
- compound composition
- chinese medicine
- percent
- traditional chinese
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention belongs to the field of Chinese medicines, and particularly relates to a Chinese medicinal compound composition for treating liver cancer. The composition consists of the following components in percentage by weight: 3-5 percent of seed of nuxvomica poison nut, 5-6 percent of huechys, 6-10 percent of gecko, 5-12 percent of ground beetle, 8-12 percent of leech, 9-10 percent of centipede, 12-19 percent of crude liquoric root and 32-40 percent of glutinous rice flour. According to the Chinese medicinal compound composition disclosed by the invention, a plurality of Chinese medicines including seed of nuxvomica poison nut, huechys, gecko, ground beetle, leech, centipede, crude liquoric root and glutinous rice flour are integrated, so that the effects of softening hard lumps, dispelling nodes and removing obstruction in channels to relieve pain are achieved, tumor growth is further restrained, and the aim of treating liver cancer is fulfilled.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Traditional Chinese medicine compound composition that is used for the treatment of hepatocarcinoma, and the method for preparing this Traditional Chinese medicine compound composition.
Background technology
Primary hepatocarcinoma (PLC, be called for short hepatocarcinoma) is one of modal malignant tumor clinically, global sickness rate increase year after year, surpassed 62.6 ten thousand/year, occupy the 5th of malignant tumor; Death occupies the 3rd of Tumor-assaciated death near 600,000/year.China is the state occurred frequently of hepatocarcinoma, and 30.6 ten thousand people's morbidities are arranged every year, and new cases account for the whole world 55%, because the hepatocarcinoma onset is hidden, aggressive is strong, when falling ill, majority of cases has belonged to middle and advanced stage, poor prognosis, mortality rate is high, is the major disease of serious threat China people health and lives.
Western medical treatment hepatocarcinoma becomes the various modes such as excision, liver transplantation, intervention embolism chemical therapeutic, radiotherapy, molecular targeted therapy by early stage single excision model at present, even but radical excision, due to reasons such as position, extrahepatic metastases and the hepatitis of the volume of hepatocarcinoma, focus, the restrictions of cirrhosis, liver dysfunction, hepatocarcinoma patient that can surgical operation therapy is only to still have 60%～70% relapse rate in 10～20%, 5 years.Because at present the chemotherapeutics selectivity is not high, in killing tumor cell, the normal cell of body also there is lethal effect; Bring out in addition the danger of secondary tumors and multidrug resistance, these factors seriously limit the clinical use of chemotherapeutics.
Chinese medicine hepatocarcinoma can be by liver cancer apoptosis reducing, suppress its proliferation-inducing cell differentiation, enhancing human body immunity function etc. reaches treatment disease purpose, effect characteristics with many target spots, and toxic and side effects is little, clinical practice can suppress liver cancer cell growth, the prolongation patient is with the tumor life span, the quality of making the life better.Yet existing Chinese medicine preparation is desirable not to the utmost to the therapeutic effect of tumor.
Summary of the invention
An object of the present invention is the technical problem that will solve for above, a kind of Traditional Chinese medicine compound composition that can effectively be applied to liver cancer treatment is provided, but the said preparation detoxicating and resolving stagnation of pathogens, and removing obstruction in the collateral to relieve pain suppresses tumor growth.
Another object of the present invention is to provide a kind of method for preparing described Traditional Chinese medicine compound composition.
For reaching above purpose, the invention provides a kind of Traditional Chinese medicine compound composition that is used for the treatment of hepatocarcinoma, its component by following percentage by weight forms: Semen Strychni 3～5%, Huechys sanguinea De Geer. 5～6%, Gekko Swinhonis 6～10%, Eupolyphaga Seu Steleophaga 5～12%, Hirudo 8～12%, Scolopendra 9～10%, Radix Glycyrrhizae 12～19%, glutinous rice flour 32～40%.
Preferably, described Traditional Chinese medicine compound composition is comprised of the component of following percentage by weight: Semen Strychni 3～5%, Huechys sanguinea De Geer. 5～6%, Gekko Swinhonis 6～9%, Eupolyphaga Seu Steleophaga 9～12%, Hirudo 9～12%, Scolopendra 9～10%, Radix Glycyrrhizae 12～19%, glutinous rice flour 32～37%.
More preferably, described Traditional Chinese medicine compound composition is comprised of the component of following percentage by weight: Semen Strychni 3.9%, Huechys sanguinea De Geer. 5.8%, Gekko Swinhonis 9.7%, Eupolyphaga Seu Steleophaga 9.7%, Hirudo 9.7%, Scolopendra 9.7%, Radix Glycyrrhizae 19.3%, glutinous rice flour 32.2%.
The present invention also provides a kind of method for preparing described Traditional Chinese medicine compound composition, and it comprises the following steps:
(1) Semen Strychni is fried to the little Huang of epidermis, heaved with coarse sand, it is standby that taking-up scrapes off crust;
(2) Huechys sanguinea De Geer. is fried to little Huang with glutinous rice flour;
(3) with whole component co-grindings, sieve, the medicated powder mix homogeneously adds refining Mel by the 1:1 weight ratio, and medicine, makes pill or capsule.
Preferably, in described step (3), 120 mesh sieves will be crossed after whole component co-grindings.
Preferably, in described step (3), adding refining Mel with described Traditional Chinese medicine compound composition weight ratio as the ratio of 1:1, and medicine, make pill.
In Traditional Chinese medicine compound composition of the present invention, Semen Strychni is the ten dry mature seeds of loganiaceae plant Semen Strychni (Strychnos nuxvomica L.); The property bitter, temperature; Very toxic.Return liver, spleen channel; Function cures mainly removing obstruction in the collateral to relieve pain, mass dissipating and swelling eliminating.Be used for traumatic injury, fracture swells and ache, rheumatoid arthritis stubborn, paralysis and numbness, skin sore, laryngopharynx swelling and pain.
Huechys sanguinea De Geer. is for to be that the dry Scorpio of cicada Huechys sanguinea De Geer., dry polypide are Long Circle, and afterbody is narrower; Toil, flat, poisonous; Function cures mainly counteracting toxic substances, the logical stasis of blood, removing mass; Scrofula is controlled in external, the tinea skin ulcer; Blood stasis amenorrhea, the lyssodexis controlled for oral administration.
Gekko Swinhonis is that the Gekkonidae animal is all without the drying of web Gekko Swinhonis Gekko swinhoana Gunther, Gekko japonicus G.japonicum Doumeril et Bibron, Gekko Swinhonis G.chinensis Gray; Salty in the mouth, cold in nature; Mild toxicity; Return Liver Channel; Function cures mainly expelling wind for relieving convulsion, detoxicating and resolving stagnation of pathogens; Be used for paralysis due to windstroke, severe and migratory arthralgia pain, wind-phlegm infantile convulsion, scrofula malignant boil.
Eupolyphaga Seu Steleophaga is the female worm dry body of Corydiidae insecticide eupolyphoge sinensis Eupolyphaga Sinesis Walker or Ji eupolyphoge sinensis Steleophaga plancyi (Boleny).Be flat avette, salty, cold; Slightly poisonous.Return Liver Channel.Removing blood stasis, reunion of fractured tendons and bones.Be used for traumatic injury, injury of tendon and muscle fracture, blood stasis amenorrhea, postpartum stagnation stomachache, abdominal mass abdominal mass mass in the abdomen.
Hirudo is the dry all of Hirudinidae animal whitmania Whitmania pigra Whitman, Hirudo Hirudo nippponica whitman or Folium Salicis Babylonicae Hirudo Whitmania acranulata Whitman.Be flat spindle, most links are arranged, salty, bitter, flat; Slightly poisonous.Return Liver Channel.Removing blood stasis stimulates the menstrual flow, the removing blood stasis abdominal mass that disappears.Be used for the blood stasis amenorrhea, lame abdominal mass mass in the abdomen, apoplectic hemiplegia, injury from falling down.
Scolopendra is for being the dry body of Scolopendridae animal Scolopendpa Subspinipes Mutilans L. KOCH Scolopendra subspinipes mutilans L.Koch.Be flat strip, suffering, temperature; Poisonous.Return Liver Channel.Function cures mainly: endogenous wind stopping spasmolytic, removing obstruction in the collateral to relieve pain, dispersing pathogen accumulation.Be used for liver-wind stirring up internally, spasm is twitched, infantile convulsion, middle air port fish sticking its mouth out of the water, hemiplegia, tetanus, rheumatoid arthritis stubborn, migraine and general headache, skin infection, scrofula, snake bite and insect sting.
Radix Glycyrrhizae is glycyrrhizic legume (dry root and the rhizome of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. Glycyrrhiza inflate Bat. or Glycyrrhiza glabra L. Glycyrrhiza glabral L..Sweet in the mouth, property is flat.GUIXIN, lung, spleen, stomach warp.Function cures mainly: invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.Be used for weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
The results show, the Traditional Chinese medicine compound composition that is used for the treatment of hepatocarcinoma provided by the invention, wherein Semen Strychni tool activating collaterals and eliminating stagnation, the merit of reducing swelling and alleviating pain, Huechys sanguinea De Geer. contains cantharidin, and the effect of broken note of the ancient Chinese eliminating stagnation is arranged, two medicines close and are monarch drug, play altogether anticancer dispersing, the effect of eliminate indigestion detumescence.Hirudo, Eupolyphaga Seu Steleophaga, Scolopendra, Gekko Swinhonis all have blood circulation promoting and blood stasis dispelling, detoxicating and resolving stagnation of pathogens, and the function of removing obstruction in the collateral to relieve pain is ministerial drug altogether, Radix Glycyrrhizae, glutinous rice flour play coordinating the actions of various ingredients in a prescription and detoxifcation, for making medicine.Above-mentioned 8 flavors share, and gather altogether hard masses softening and resolving, the effect of removing obstruction in the collateral to relieve pain, and then suppress tumor growth, reach the purpose of Hepatoma therapy.
The specific embodiment
Below in conjunction with specific embodiment, technical scheme of the present invention is done further detailed description, but protection scope of the present invention is not limited in following examples.
Embodiment 1
1. by following each component of formula weighing:
Semen Strychni 18g, Huechys sanguinea De Geer. 27g, Gekko Swinhonis 45g, Eupolyphaga Seu Steleophaga 45g, Hirudo 45g, Scolopendra 45g, Radix Glycyrrhizae 90g, glutinous rice flour 150g.
2. prepare according to the following steps compositions:
(1) the 18g Semen Strychni is fried to the little Huang of epidermis, heaved with coarse sand, it is standby that taking-up scrapes off crust;
(2) the 27g Huechys sanguinea De Geer. is fried to little Huang with the 150g glutinous rice flour;
(3) with whole component co-grindings, cross 120 mesh sieves, the medicated powder mix homogeneously adds refining Mel in the 1:1 ratio, and medicine, makes the ball piece, then makes pill with pellet processing machine, drying, packing and get final product the heavy 0.08g of every pill.
Embodiment 2
1. by following each component of formula weighing:
Semen Strychni 9g, Huechys sanguinea De Geer. 15g, Gekko Swinhonis 15g, Eupolyphaga Seu Steleophaga 30g, Hirudo 30g, Scolopendra 22.5g, Radix Glycyrrhizae 30g, glutinous rice flour 90g.
2. prepare according to the following steps compositions:
(1) the 9g Semen Strychni is fried to the little Huang of epidermis, heaved with coarse sand, it is standby that taking-up scrapes off crust;
(2) the 15g Huechys sanguinea De Geer. is fried to little Huang with the 90g glutinous rice flour;
(3) with whole component co-grindings, cross 120 mesh sieves, the medicated powder mix homogeneously, filled capsules namely gets capsule, the 0.35g/ grain.
Embodiment 3
1. by following each component of formula weighing:
Semen Strychni 15g, Huechys sanguinea De Geer. 18g, Gekko Swinhonis 30g, Eupolyphaga Seu Steleophaga 15g, Hirudo 24g, Scolopendra 30g, Radix Glycyrrhizae 45g, glutinous rice flour 120g.
2. prepare according to the following steps compositions:
(1) the 9g Semen Strychni is fried to the little Huang of epidermis, heaved with coarse sand, it is standby that taking-up scrapes off crust;
(2) the 15g Huechys sanguinea De Geer. is fried to little Huang with the 90g glutinous rice flour;
(3) with whole component co-grindings, cross 120 mesh sieves, the medicated powder mix homogeneously adds refining Mel in the 1:1 ratio, and medicine, makes the ball piece, then makes pill with pellet processing machine, drying, packing and get final product the heavy 0.08g of every pill.
Pharmacodynamics experimental study in the anti-hepatocarcinoma body of embodiment 4
(1) experiment material and method
1. experiment material
1.1 medicine
Treatment group 1 for the reagent thing: get the Traditional Chinese medicine compound composition of embodiment 1 gained, in addition distilled water dissolving is made into the medicinal liquid that active ingredient concentration is 0.075Kg/L.
Treatment group 2 for the reagent thing: get the Traditional Chinese medicine compound composition of embodiment 2 gained, in addition distilled water dissolving is made into the medicinal liquid that active ingredient concentration is 0.075Kg/L.
Treatment group 3 for the reagent thing: get the Traditional Chinese medicine compound composition of embodiment 3 gained, in addition distilled water dissolving is made into the medicinal liquid that active ingredient concentration is 0.075Kg/L.
Herein, " effective ingredient " refers to Semen Strychni, Huechys sanguinea De Geer., Gekko Swinhonis, Eupolyphaga Seu Steleophaga, Hirudo, Scolopendra, Radix Glycyrrhizae and glutinous rice flour.
1.2 laboratory animal:
SPF level Kunming mouse, male, in age in 6-8 week, body weight 20 ± 2g is available from Guangdong Medical Lab Animal Center.The animal quality quality certification number: 0093631, credit number: SCXK(Guangdong) 2008-0002.The animal feeding environment: room temperature is 23 ± 2 ℃, and relative humidity is 40-75%, adopts standard feed and water to raise.
1.3 tumor cell line:
Mice H22 hepatoma cell strain after mouse peritoneal inoculation 7～8d, extracts ascites, as the tumor kind that goes down to posterity available from Zhongshan University's medical college animal center cell bank under aseptic condition.
1.4 putting, serum IL-2 exempts from the method detection kit:
Provided by Beijing pul great achievement bio tech ltd.
1.5 experimental apparatus:
The SN-695B type is put and is exempted from measuring instrument (Shanghai day ring instrument one factory), TLL-C tabletop refrigerated centrifuge (Fourth Ring, Beijing scientific instrument factory), GB303 electronic analytical balance.
2. experimental technique
2.1. modeling method
Tumor strain inoculation method is according to the method for the 3rd national oncology pharmacology in 1989 and chemotherapy academic conference regulation and optimize and improve.Get the milky cancer ascites of H22 ascites hepatocarcinoma tumor-bearing mice, dilute with normal saline l:3; And the counting cancerous cell, contain 1 * 10
7Individual cell/m1, every right side of mice axillary fossa subcutaneous vaccination 0.2ml, preparation H22 hepatocarcinoma tumor-bearing mice.
2.2 tumor suppression experiment
50 Male Kunming strain mice prepare hepatocarcinoma tumor-bearing mice mouse model as stated above, after modeling 24h, mice are divided into 5 groups at random, 10 every group, are respectively: model group, treatment group 1～3 and treated with cyclophosphamide pulse group.The dosage for the treatment of group 1-3 is all by 1.48g/kg body weight (being equivalent to clinical medicine dose after conversion) gastric infusion, the dosage of cyclophosphamide group is equivalent to clinical medicine dose after converting by 20mg/kg() intraperitoneal injection, model group is given equal-volume normal saline gavage, every day 1 time, continuous 8 days, after last administration 24h, mice is weighed, the blood sampling of mouse orbit venous plexus, centrifugal, separation of serum, disconnected neck is put to death mice, gets the subcutaneous tumors piece and weighs.
2.3 serum IL-2 horizontal detection:
The method of exempting from is put in employing, presses the operation of test kit description.
3. therapeutic evaluation
3.1 solid tumor therapeutic evaluation
The curative effect of solid tumor represents with tumour inhibiting rate:
Tumour inhibiting rate (%)=[(the average tumor of the average tumor weight-corresponding administration group of model group is heavy)/average tumor of model group is heavy] * 100%
3.2 Drug efficacy evaluation standard
Requirement matched group tumor weight-average value must not be lower than 1g; Experimental therapy group average weight descends (before and after administration, self compares) must not be over 15%; Death toll must not surpass 20%; The heavy suppression ratio of tumor is greater than 30% and repeated trials 3 times, and stable curative effect has significant difference person with matched group, can think that this medicine has certain curative effect.
4. statistical procedures:
Measurement data is with mean ± standard deviation
Expression adopts the SPSS10.0 software kit to carry out statistical analysis, and One way ANOVA is adopted in the analysis of many Sets of Measurement Datas, and multiple comparisons adopts LSD, with P＜0.05 expression difference, significant is arranged.
(2) result
1. general status and body weight change before and after medication
Mice activity before modeling, diet, hair color are all without abnormal.Test the 5th day mice oxter and can touch tumor.It is all very fast that medication is in earlier stage respectively organized the Mouse Weight increase, and later stage cyclophosphamide group body weight increase is slowed down.Respectively organize Mouse Weight no significant difference (P〉0.05) before experiment, cyclophosphamide group and model group comparison when experiment finishes, the body weight difference of mice has significant (P＜0.05), sees Table 1.
Body weight change before and after table 1. medication
Annotate: compare * P＜0.05 with model group
2. the Traditional Chinese medicine compound composition impact heavy on H22 transplanted human hepatocellular carcinoma mouse tumor
With model group relatively, treatment group 1, treatment group 2 and treatment group 3 tumors are heavy obviously reduces, difference all has significant (P＜0.01), with the cyclophosphamide group relatively, difference there are no significant meaning (P〉0.05); The tumour inhibiting rate for the treatment of group 1 sees Table 2 higher than treatment group 2 and treatment group 3.
The impact that table 2. Chinese medicine compound is heavy on H22 transplanted human hepatocellular carcinoma mouse tumor
Annotate: compare * P＜0.01 with model group.
3. the impact of Chinese medicine compound on H22 transplanted human hepatocellular carcinoma mice serum IL-2 content
Treatment group 1 serum IL-2 level is apparently higher than model group, and difference has significant (P＜0.01).
Treatment group 2 and treatment group 3 serum IL-2 levels are starkly lower than treatment group 1, and difference all has significant (P＜0.05,0.01), sees Table 3.
The impact of table 3. Chinese medicine compound on H22 transplanted human hepatocellular carcinoma mice serum IL-2 content
Annotate: compare △ P＜0.01 with model group; Compare * P＜0.05, * * P＜0.01 with treatment group 1; Compare #P＜0.01 with the cyclophosphamide group.
(3) conclusion
By above results of animal as seen, Traditional Chinese medicine compound composition provided by the invention has H22 transplanted human hepatocellular carcinoma mice and suppresses preferably the tumor growth effect, especially best with the action effect for the treatment of group 1, the Chinese drug-treated group administered of prompting embodiment 1 is better, its mechanism of action with regulate immunologic function, rising mice serum IL-2 level is closely related.
The embodiment 5 external effect experimental studies of anti-liver cancer drug
1 materials and methods
1.1 experimental cell Huh7 cell line, the biotech firm of fighting provides by Guangzhou indigo plant.
1.2 Contained Serum preparation:
6 of SPF level New Zealand white rabbit, male and female half and half, body weight 1.8kg left and right, be divided at random 3 groups, every group 2, be respectively normal group, the red ball group of Chinese medicine compound group (47.74g/Kg) and horse (44.60g/Kg), the equal gastric infusion of each administration treated animal, dosage=quantity * dose,equivalent coefficient (pressing body surface area calculates) * 2, every day 1 time, continuous 3d, 12h before last 1 administration, water is can't help in fasting, anaesthetize after administration 2h, blood sampling, centrifugal, get supernatant, be Contained Serum, the normal group animal gives equal-volume physiology distilled water gavage, continuous 3d, get serum and be not Contained Serum.Then all process with 0.22 μ m filtering with microporous membrane degerming, 56 ℃ of deactivation 30min ,-2O ℃ of refrigerator is frozen standby.Add before use and contain 10% hyclone DMEM culture fluid furnishing desired concn.
1.3 main agents and instrument
DMEM in high glucose culture fluid, hyclone are available from U.S. GIBCO company; Dimethylthiazole diphenyl Thiazolyl blue tetrazolium bromide salt (MTT), dimethyl sulfoxide (DMSO) and trypsin are all available from sigma company; Ethylenediaminetetraacetic acid (EDTA) is available from Shanghai bio-engineering corporation (U.S. Amreeso import packing); Penicillin, streptomycin are available from North China pharmaceutical Co. Ltd.
1.4 cell culture
People's hepatocarcinoma Huh7 cell is put in culture bottle with the DMEM culture fluid that contains penicillin, each 100U/mL of streptomycin, volume fraction 10% hyclone, cultivates in the CO2 incubator of 5%CO2,37 ℃ of saturated humidities, and 2～3d changes 1 culture fluid.When cell grows to 80%～90% density, with 0.2g/L EDTA and 2.5g/L trypsinization, under inverted microscope, the observation of cell form becomes circle, intercellular substance discards pancreatin when becoming large, collecting cell, the centrifugal supernatant re-suspended cell of abandoning goes down to posterity by 1:3～1:4 and cultivates or choose the exponential phase cell and test.
1.5 the Chinese medicine compound group the red ball group of horse on the impact of Huh7 cell proliferation relatively
Adopt mtt assay.With the Huh7 cell that goes down to posterity with 1.0 * l0
5The density 0.1mL of/mL is inoculated in 96 orifice plates, be placed in 37 ℃, saturated humidity, 5%CO2 incubator and cultivate, after cultivating 24h, inhale and abandon supernatant, be divided into 3 groups: the red ball group of Normal group, blank serum group, Chinese medicine compound group and horse, each concentration group are all established 4 multiple holes.Normal group adds the DMEM culture fluid that contains 10% hyclone.Treatment group adds respectively Traditional Chinese medicine compound composition and the red ball Contained Serum of horse that has prepared, and the serum matched group adds not Contained Serum.All cultivate with the DMEM culture fluid of 10% hyclone.Each group all after cultivation 24,48h, 72h, is inhaled gently and is abandoned supernatant, adds MTT, puts into incubator, cultivates 4h, then with DMSO, it is dissolved, and measures D value (490nm), the action effect of comparative drug with microplate reader thereafter.
1.6. statistical procedures:
Measurement data is with mean ± standard deviation
Expression adopts the SPSS10.0 software kit to carry out statistical analysis, and One way ANOVA is adopted in the analysis of many Sets of Measurement Datas, and multiple comparisons adopts LSD, with P＜0.05 expression difference, significant is arranged.
2 results
Detect the different time points Chinese medicine compound to the impact of people's hepatocarcinoma Huh7 cell proliferation with mtt assay:
At pharmaceutically-active 24h, cell begins to occur the apoptosis phenomenon, under mirror as seen: cell shrinkage occurs, take off wall, cell is floating and the cell breakage phenomenon, apoptosis increases, the red ball of Traditional Chinese medicine compound composition of the present invention and horse all has and suppresses preferably the cel l proliferation effect, and effect all is better than the red ball group of horse (p＜0.01), show that Traditional Chinese medicine compound composition of the present invention can significantly suppress Huh7 propagation, and effect is stable.See Table 4.
Table 4. different time points Chinese medicine compound on the impact of hepatocarcinoma Huh7 cell proliferation (
N=4)
Annotate: 1. p＜0.01, with the blank group; 2. p＜0.01, compare with the serum matched group; 3. p＜0.01, compare with the red ball group of horse.
3 conclusions
Traditional Chinese medicine compound composition of the present invention external have suppress preferably the Huh7 cel l proliferation, and effect is better than the red ball of horse.
Claims (6)
1. a Traditional Chinese medicine compound composition that is used for the treatment of hepatocarcinoma, is characterized in that being comprised of the component of following percentage by weight: Semen Strychni 3～5%, Huechys sanguinea De Geer. 5～6%, Gekko Swinhonis 6～10%, Eupolyphaga Seu Steleophaga 5～12%, Hirudo 8～12%, Scolopendra 9～10%, Radix Glycyrrhizae 12～19%, glutinous rice flour 32～40%.
2. Traditional Chinese medicine compound composition according to claim 1, is characterized in that being comprised of the component of following percentage by weight: Semen Strychni 3～5%, Huechys sanguinea De Geer. 5～6%, Gekko Swinhonis 6～9%, Eupolyphaga Seu Steleophaga 9～12%, Hirudo 9～12%, Scolopendra 9～10%, Radix Glycyrrhizae 12～19%, glutinous rice flour 32～37%.
3. Traditional Chinese medicine compound composition according to claim 1, is characterized in that being comprised of the component of following percentage by weight: Semen Strychni 3.9%, Huechys sanguinea De Geer. 5.8%, Gekko Swinhonis 9.7%, Eupolyphaga Seu Steleophaga 9.7%, Hirudo 9.7%, Scolopendra 9.7%, Radix Glycyrrhizae 19.3%, glutinous rice flour 32.2%.
4. the method for preparing the described Traditional Chinese medicine compound composition of claims 1 to 3 any one is characterized in that comprising the following steps:
(1) Semen Strychni is fried to the little Huang of epidermis, heaved with coarse sand, it is standby that taking-up scrapes off crust;
(2) Huechys sanguinea De Geer. is fried to little Huang with glutinous rice flour;
(3) with whole component co-grindings, sieve, the medicated powder mix homogeneously is further made pill or capsule.
5. method according to claim 4, is characterized in that: in described step (3), will cross 120 mesh sieves after whole component co-grindings.
6. method according to claim 4 is characterized in that: in described step (3), and adding refining Mel with described Traditional Chinese medicine compound composition weight ratio as the ratio of 1:1, and medicine, make pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104512777A CN102940683B (en) | 2012-11-12 | 2012-11-12 | Chinese medicinal compound composition for treating liver cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104512777A CN102940683B (en) | 2012-11-12 | 2012-11-12 | Chinese medicinal compound composition for treating liver cancer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940683A CN102940683A (en) | 2013-02-27 |
| CN102940683B true CN102940683B (en) | 2013-11-06 |
Family
ID=47723743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104512777A Active CN102940683B (en) | 2012-11-12 | 2012-11-12 | Chinese medicinal compound composition for treating liver cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940683B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623057A (en) * | 2013-10-24 | 2014-03-12 | 刘长城 | Anti-cancer traditional Chinese medicinal composition, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416851A (en) * | 2001-11-08 | 2003-05-14 | 胡景夫 | Plaster for treating cancerous pain |
| CN101411744A (en) * | 2007-10-19 | 2009-04-22 | 李廷树 | Medicament for treating neoplastic disease |
-
2012
- 2012-11-12 CN CN2012104512777A patent/CN102940683B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416851A (en) * | 2001-11-08 | 2003-05-14 | 胡景夫 | Plaster for treating cancerous pain |
| CN101411744A (en) * | 2007-10-19 | 2009-04-22 | 李廷树 | Medicament for treating neoplastic disease |
Non-Patent Citations (4)
| Title |
|---|
| 刘琳，等.中医"以毒攻毒"法治疗恶性肿瘤的研究述评.《湖南中医药导报》.1999,第5卷(第2期),9-11. |
| 刘琳,等.中医"以毒攻毒"法治疗恶性肿瘤的研究述评.《湖南中医药导报》.1999,第5卷(第2期),9-11. * |
| 虫类药治疗癌性疼痛26例分析;郑铁豪;《广西医科大学学报》;20071231;第14卷(第1期);94-95 * |
| 郑铁豪.虫类药治疗癌性疼痛26例分析.《广西医科大学学报》.2007,第14卷(第1期),94-95. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940683A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN101849999B (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN108567820A (en) | A kind of Chinese medicine composition and preparation method thereof for oncotherapy | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102188638A (en) | Medicament for treating liver cancer | |
| CN102940683B (en) | Chinese medicinal compound composition for treating liver cancer and preparation method thereof | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN101590209B (en) | Medicament for treating tumors and preparation method thereof | |
| CN102058854B (en) | Chinese medicine for treating malignant lymphoma | |
| CN101293060B (en) | Traditional Chinese medicine for treating cytology specification adenocarcinoma | |
| CN103977256A (en) | Medicine composition for treating cancer | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN101745052B (en) | Medicament for treating tumors and preparation method thereof | |
| CN102631409A (en) | Health-care medicine formula with functions of enhancing immunity, alleviating physical fatigue and resisting tumor | |
| CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
| CN103656032A (en) | Chinese patent medicine for treating mammitis and mastocarcinoma and preparation method thereof | |
| CN103028079A (en) | Pharmaceutical composition for preventing and treating brain tumor and preparation method | |
| CN107184912A (en) | The positive disperse accumulations compound preparation of one breeding and its application | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition | |
| CN104524284A (en) | Medicine for preventing and treating flu | |
| CN104491490A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN104055949B (en) | Traditional Chinese medicine compound composition for the treatment of cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |